Literature DB >> 16810343

Diabetes, insulin, and risk of cancer.

R Schiel1, W Beltschikow, T Steiner, G Stein.   

Abstract

Up to now, the studies involving diabetes mellitus and malignancies show controversial results: Many of them have found incidences of malignancies that were comparable or even lower than those in nondiabetic subjects; others conclude that diabetes mellitus is linked to a higher incidence of malignancies and/or a predictor of mortality from cancer. Insulin and its precursors, pro- and pre-proinsulin, have been shown to have some homology to the insulin-like growth factors, but, moreover they have some affinity to bind at receptors of the tumor growth factor and some hybrids too. Hence, an association between diabetes mellitus, insulin, hyperinsulinaemia, and carcinogenesis appears plausible. On the other hand, diabetes mellitus can influence different hormone levels. In some tumor entities, such as prostate carcinoma, this effect can somewhat counterbalance the direct mitogene effect of insulin and its precursors. All in all, as a result of the complexity of these mechanisms and the differences between the tumor entities, the question whether diabetes mellitus is associated with an increased or a reduced risk for the development and in respect of the prognosis of cancer cannot be answered. The only way to give some answer is to focus on specific tumor entities: It seems that diabetes mellitus and/or hyperglycaemia are independent risk factors and/or predictors at least in respect of cancer of the colon, pancreas, female breast, endometrium, and, in men, of the liver and bladder. However, most of these data were assessed in patients with type 2 diabetes mellitus. This makes it highly questionable whether the data can easily be transferred to patients with type 1 diabetes. Moreover, additional potential limitations are that most of the studies do not focus on the treatment modality or the race of participants. In conclusion, up to the present, we have an increased risk for some and a reduced risk for other tumor entities, but still, we cannot give the general answer. Copyright 2006 Prous Science

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16810343     DOI: 10.1358/mf.2006.28.3.985230

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  12 in total

1.  Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.

Authors:  Valter Donadon; Massimiliano Balbi; Pietro Casarin; Alessandro Vario; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

2.  Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region.

Authors:  E K K Lam; G D Batty; R R Huxley; A L C Martiniuk; F Barzi; T H Lam; C M M Lawes; G G Giles; T Welborn; H Ueshima; A Tamakoshi; J Woo; H C Kim; X Fang; S Czernichow; M Woodward
Journal:  Ann Oncol       Date:  2010-08-12       Impact factor: 32.976

3.  Akt and phospholipase Cγ are involved in the regulation of growth and migration of MDA-MB-468 breast cancer and SW480 colon cancer cells when cultured with diabetogenic levels of glucose and insulin.

Authors:  Nicola M Tomas; Kai Masur; Jonas C Piecha; Bernd Niggemann; Kurt S Zänker
Journal:  BMC Res Notes       Date:  2012-07-10

Review 4.  Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.

Authors:  Biagio Arcidiacono; Stefania Iiritano; Aurora Nocera; Katiuscia Possidente; Maria T Nevolo; Valeria Ventura; Daniela Foti; Eusebio Chiefari; Antonio Brunetti
Journal:  Exp Diabetes Res       Date:  2012-06-04

5.  Exercise training prevents endometrial hyperplasia and biomarkers for endometrial cancer in rat model of type 1 diabetes.

Authors:  Muhammed Al-Jarrah; Ismail Matalka; Hasan Al Aseri; Alia Mohtaseb; Irina V Smirnova; Lesya Novikova; Lisa Stehno-Bittel; Ahed Alkhateeb
Journal:  J Clin Med Res       Date:  2010-10-11

6.  PPARgamma and MEK Interactions in Cancer.

Authors:  Elke Burgermeister; Rony Seger
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

7.  New target genes for the peroxisome proliferator-activated receptor-γ (PPARγ) antitumour activity: Perspectives from the insulin receptor.

Authors:  Daniela P Foti; Francesco Paonessa; Eusebio Chiefari; Antonio Brunetti
Journal:  PPAR Res       Date:  2009-06-29       Impact factor: 4.964

8.  Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.

Authors:  Maria E Ramos-Nino; Charles D MacLean; Benjamin Littenberg
Journal:  BMC Med       Date:  2007-06-21       Impact factor: 8.775

9.  A Population-Based Cohort Study of All-Cause and Site-Specific Cancer Incidence Among Patients With Type 1 Diabetes Mellitus in Taiwan.

Authors:  Pei-Chun Hsu; Wei-Hung Lin; Te-Hui Kuo; Hui-Mei Lee; Chieh Kuo; Chung-Yi Li
Journal:  J Epidemiol       Date:  2015-07-25       Impact factor: 3.211

10.  Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis.

Authors:  Jung Hoon Cha; Si Hyun Bae; Hye Lim Kim; Na Ri Park; Eun Suk Choi; Eun Sun Jung; Jong Young Choi; Seung Kew Yoon
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.